Frequency-doubled Nd:YAG laser for the treatment of exudative diabetic maculopathy.
To determine the clinical efficacy of frequency-doubled Nd:YAG (FD YAG) laser for the treatment of diabetic clinically significant macular oedema (CSMO). A prospective pilot study was carried out on 55 eyes with CSMO. FD YAG laser exposures were applied in a focal or grid pattern. The results were evaluated by Snellen visual acuity, slit-lamp biomicroscopy, colour photography and fundus fluorescein angiography. At mean review of 5.3 months, macular oedema had resolved either completely or partly in 44 (80%) eyes, was unchanged in 10 (18%) eyes and progressed in 1 (2%) eye. Visual acuity improved in 11 (20%), stabilised in 40 (73%) and deteriorated in 4 (7%) eyes. FD YAG laser therapy is effective in the treatment of CSMO. It combines the ergonomic advantages of a solid-state laser with the benefits of its wavelength. A comparison between the clinical results of FD YAG and other lasers used in the treatment of CSMO is, however, required.